Cwm LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 26.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 25,966 shares of the medical device company’s stock after selling 9,255 shares during the period. Cwm LLC’s holdings in DexCom were worth $3,714,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of DXCM. Cerebellum GP LLC acquired a new position in DexCom in the 2nd quarter valued at $171,000. Clinton Group Inc. acquired a new position in DexCom in the 2nd quarter valued at $201,000. Strs Ohio acquired a new position in DexCom in the 3rd quarter valued at $213,000. Bank Pictet & Cie Asia Ltd. acquired a new position in DexCom in the 2nd quarter valued at $218,000. Finally, Accredited Investors Inc. acquired a new position in DexCom in the 2nd quarter valued at $225,000.
A number of research analysts have commented on DXCM shares. Stephens reaffirmed a “buy” rating and issued a $135.00 price objective on shares of DexCom in a report on Thursday, August 2nd. Bank of America upped their price objective on DexCom from $106.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Canaccord Genuity upped their price objective on DexCom from $105.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Jefferies Financial Group upped their price objective on DexCom from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Oppenheimer set a $125.00 price objective on DexCom and gave the company a “buy” rating in a report on Thursday, August 2nd. Eight research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. DexCom presently has an average rating of “Buy” and a consensus target price of $129.06.
DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, August 1st. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.08. The company had revenue of $242.50 million for the quarter, compared to analyst estimates of $205.81 million. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. DexCom’s quarterly revenue was up 42.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.16) EPS. As a group, equities research analysts expect that DexCom, Inc. will post -0.47 earnings per share for the current fiscal year.
In other news, EVP Steven Robert Pacelli sold 3,114 shares of the stock in a transaction on Tuesday, October 23rd. The stock was sold at an average price of $128.85, for a total transaction of $401,238.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $124.25, for a total value of $621,250.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 182,692 shares of company stock worth $24,908,639. 1.80% of the stock is currently owned by insiders.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Find a Trading Strategy That Works
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.